Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

428P - Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Hong Qiu

Citation

Annals of Oncology (2021) 32 (suppl_5): S530-S582. 10.1016/annonc/annonc698

Authors

H. Qiu, Y. Dai, T. Huang, L. Sun, L. Zhuang, M. Zhang, Y. Zou, X. Yuan

Author affiliations

  • Department Of Oncology, Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 - Wu Han/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 428P

Background

Colorectal cancer (CRC) is the fifth most common cancer and one of the leading causes of cancer-related death in China. Although apatinib and S-1, respectively, are used in the treatment of advanced colorectal cancer, the efficacy and safety of the combination of the two drugs are unclear. The aim of this study was to investigate the efficacy and safety of low-dose apatinib plus S-1 compared with regorafenib and fruquintinib in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.

Methods

Records of 114 patients with refractory mCRC in our center from April 2016 to 17 September 2020 were retrospectively reviewed. Among these patients, 43 received apatinib 250mg/day combined with S-1, 36 received regorafenib starting at 80mg/day with weekly escalation, and 35 received fruquintinib.

Results

The median progression-free survival was 3.9 months [95% confidence interval (CI),2.5-5.3 months] in the apatinib plus S-1 group, 3.1 months (95% CI 1.9-4.2 months) in the fruquintinib group, and 2.4 months (95% CI 2.1-2.7 months) in the regorafenib group, the mPFS of apatinib plus S-1 was significantly longer than that of regorafenib. The median overall survival was 8.2 months (95%CI,5.4-11.0 months) in the apatinib plus S-1 group, 7.8 months (95%CI,5.3-10.3 months) in the fruquintinib group, and 7.5 months (95%CI, 4.2-10.7 months) in the regorafenib group, which was comparable among the three groups. Disease control rate (DCR) was 83.7% in the apatinib plus S-1 group, 71.4% in the fruquintinib group, and 66.7% in the regorafenib group, and no significant difference was shown among the three groups. Patients in the apatinib plus S-1 group had a higher incidence of hematological toxicity including anemia, leukopenia, and thrombocytopenia, and the hand-foot skin reaction was more prevalent in the regorafenib group, while the adverse reaction of hypertension in the fruquintinib group was very significant.

Conclusions

Low-dose apatinib plus S-1 prolonged PFS compared with regorafenib, and is a promising clinical regimen for the treatment of refractory mCRC with tolerable and controlled toxicity that is worth studying in the future.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Hong Qiu.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.